LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB
CJDQ443E12101
Phase 2 small_molecule active
Quick answer
LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB for Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active